StockData
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. (TCRX) stock

TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15+0.01 (+4.07%)

Close on Nov 17, 2026Market cap $10.23MP/E –Yield –

TScan Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

For fiscal 2025 it was -$132.91M. The highest annual figure on record is -$25.03M in fiscal 2020.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$132.91M–
FY2024Dec 31, 2024-$130.72M–
FY2023Dec 31, 2023-$88.06M–
FY2022Dec 31, 2022-$61.54M–
FY2021Dec 31, 2021-$45.34M–
FY2020Dec 31, 2020-$25.03M–

More TScan Therapeutics figures

See a number that looks wrong?